[go: up one dir, main page]

ECSP014106A - Interleuquina 2 estabilizada - Google Patents

Interleuquina 2 estabilizada

Info

Publication number
ECSP014106A
ECSP014106A EC2001004106A ECSP014106A ECSP014106A EC SP014106 A ECSP014106 A EC SP014106A EC 2001004106 A EC2001004106 A EC 2001004106A EC SP014106 A ECSP014106 A EC SP014106A EC SP014106 A ECSP014106 A EC SP014106A
Authority
EC
Ecuador
Prior art keywords
interleuquina
stabilized
variant
preferred formulation
reconstitution
Prior art date
Application number
EC2001004106A
Other languages
English (en)
Inventor
Weibo Wang
Michael Shearer
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24424265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP014106(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of ECSP014106A publication Critical patent/ECSP014106A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Train Traffic Observation, Control, And Security (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Sub-Exchange Stations And Push- Button Telephones (AREA)

Abstract

Una preparación farmacéutica estable que comprende interleuquina-2 humana o una variante de la misma y una cantidad estabilizante de histidina una formulación preferida incluye glicina y sacarosa y una variante de II-2 que tiene una mutación simple, N88R. La formulación preferida es en forma leofilizada que con la reconstitución con un diluyente acuoso, produce una solución que tiene un ph que varia desde aproximadamente 5,0 a 6,5.
EC2001004106A 2000-06-28 2001-06-27 Interleuquina 2 estabilizada ECSP014106A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/605,577 US6689353B1 (en) 2000-06-28 2000-06-28 Stabilized interleukin 2

Publications (1)

Publication Number Publication Date
ECSP014106A true ECSP014106A (es) 2002-02-25

Family

ID=24424265

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2001004106A ECSP014106A (es) 2000-06-28 2001-06-27 Interleuquina 2 estabilizada

Country Status (24)

Country Link
US (1) US6689353B1 (es)
EP (1) EP1370280B1 (es)
JP (3) JP5522878B2 (es)
KR (1) KR100799402B1 (es)
CN (1) CN1523997B (es)
AR (1) AR029139A1 (es)
AU (1) AU2001273063A1 (es)
BR (1) BR0112101B1 (es)
CA (1) CA2413334C (es)
CO (1) CO5290308A1 (es)
CU (1) CU23536A3 (es)
DE (1) DE60142412D1 (es)
DO (1) DOP2001000197A (es)
EC (1) ECSP014106A (es)
ES (1) ES2344729T3 (es)
HN (1) HN2001000139A (es)
IL (2) IL153587A0 (es)
MX (1) MXPA03000046A (es)
MY (1) MY128629A (es)
PE (1) PE20020127A1 (es)
SV (1) SV2002000512A (es)
TW (1) TWI235063B (es)
UY (1) UY26805A1 (es)
WO (1) WO2002000243A2 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8531276B2 (en) * 2000-03-15 2013-09-10 Logitech Europe S.A. State-based remote control system
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2004028557A1 (ja) * 2002-09-26 2004-04-08 Shionogi & Co., Ltd. 安定化されたタンパク組成物
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
SG151298A1 (en) * 2004-04-08 2009-04-30 Biomatrica Inc Integration of sample storage and sample management for life science
JP2008531722A (ja) 2005-03-04 2008-08-14 ダイナバックス テクノロジーズ コーポレイション 構造的に安定なコンジュゲート分子を含む組成物
CA2643693A1 (en) * 2006-03-10 2007-09-20 Dyax Corp. Formulations for ecallantide
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CA2810522A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Polymorphs
JP2010530846A (ja) * 2007-06-01 2010-09-16 アコロジックス インコーポレイティッド 高温で安定なペプチド製剤
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101820024B1 (ko) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
CA2761675A1 (en) * 2009-05-11 2010-11-18 Biomatrica, Inc. Compositions and methods for biological sample storage
LT2498801T (lt) 2009-11-13 2018-05-10 Sanofi-Aventis Deutschland Gmbh Farmacinė kompozicija, apimanti despro36eksendin-4(1-39)-lys6-nh2 ir metioniną
PL3417871T3 (pl) 2009-11-13 2021-06-14 Sanofi-Aventis Deutschland Gmbh Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
MX366325B (es) 2010-05-05 2019-07-05 Boehringer Ingelheim Int Terapia de combinacion.
EP2598660B1 (en) 2010-07-26 2017-03-15 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
CA2806734A1 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
MX339614B (es) 2010-08-30 2016-06-02 Sanofi - Aventis Deutschland GmbH Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
KR102349549B1 (ko) 2010-11-12 2022-01-11 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
AU2011336413B2 (en) * 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2014100755A2 (en) 2012-12-20 2014-06-26 Biomatrica, Inc. Formulations and methods for stabilizing pcr reagents
CN103063829B (zh) * 2012-12-21 2015-01-14 杭州茂天赛科技有限公司 一种冻存液
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP6661554B2 (ja) 2014-06-10 2020-03-11 バイオマトリカ，インク． 周囲温度における血小板の安定化
PL3482766T3 (pl) 2014-08-11 2020-11-16 Delinia, Inc. Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych
CA2970200A1 (en) 2014-12-12 2016-06-16 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
KR102589056B1 (ko) 2015-12-08 2023-10-12 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN110167957A (zh) 2016-11-08 2019-08-23 德里尼亚公司 用于治疗自身免疫疾病的il-2变体
CN110520436A (zh) 2017-03-15 2019-11-29 潘迪恩治疗公司 靶向免疫耐受性
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
MX2020005041A (es) 2017-11-21 2020-10-12 Univ Leland Stanford Junior Agonistas parciales de interleucina-2.
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
JP7490563B2 (ja) 2018-03-28 2024-05-27 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス Ｉｌ－２コンジュゲート
KR20220035333A (ko) 2019-05-20 2022-03-22 팬디온 오퍼레이션스, 인코포레이티드 Madcam 표적 면역관용
WO2021127262A1 (en) 2019-12-17 2021-06-24 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
CA3164731A1 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
WO2021245130A1 (en) 2020-06-03 2021-12-09 Ascendis Pharma Oncology Division A/S Il-2 sequences and uses thereof
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CA3201446A1 (en) * 2020-11-13 2022-05-19 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60215631A (ja) * 1984-04-09 1985-10-29 Takeda Chem Ind Ltd インタ−ロイキン−２組成物
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
JPH0645551B2 (ja) * 1986-01-07 1994-06-15 塩野義製薬株式会社 インタ−ロイキン−２組成物
JPH0229016A (ja) * 1989-06-09 1990-01-31 Alpine Electron Inc イコライザ装置
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US6509023B1 (en) * 1997-07-31 2003-01-21 Rhodia Chimie Cosmetic composition comprising a functionalized polyorganosiloxane
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2

Also Published As

Publication number Publication date
CN1523997A (zh) 2004-08-25
DE60142412D1 (de) 2010-07-29
CA2413334C (en) 2011-03-08
BR0112101B1 (pt) 2017-11-14
WO2002000243A3 (en) 2003-10-02
AU2001273063A1 (en) 2002-01-08
CO5290308A1 (es) 2003-06-27
KR100799402B1 (ko) 2008-01-30
US6689353B1 (en) 2004-02-10
CA2413334A1 (en) 2002-01-03
JP5989728B2 (ja) 2016-09-07
IL153587A0 (en) 2003-07-06
MXPA03000046A (es) 2003-06-19
IL153587A (en) 2007-12-03
WO2002000243A2 (en) 2002-01-03
EP1370280A2 (en) 2003-12-17
JP5522878B2 (ja) 2014-06-18
DOP2001000197A (es) 2003-01-15
AR029139A1 (es) 2003-06-04
MY128629A (en) 2007-02-28
KR20030016312A (ko) 2003-02-26
SV2002000512A (es) 2002-07-03
UY26805A1 (es) 2002-01-31
TWI235063B (en) 2005-07-01
ES2344729T3 (es) 2010-09-06
CN1523997B (zh) 2010-09-01
JP2015007114A (ja) 2015-01-15
EP1370280B1 (en) 2010-06-16
PE20020127A1 (es) 2002-04-27
CU23536A3 (es) 2010-06-17
JP2004532791A (ja) 2004-10-28
BR0112101A (pt) 2004-07-06
JP2012211166A (ja) 2012-11-01
HN2001000139A (es) 2003-12-11

Similar Documents

Publication Publication Date Title
ECSP014106A (es) Interleuquina 2 estabilizada
CY1113353T1 (el) Φαρμακοτεχνικη μορφη αντι-τνf-αλφα αντισωματος
DE59912393D1 (de) Vakzinformulierung enthaltend Zuckeralkohol und niedrige Konzentrationen anorganischer Ionen
ATE205090T1 (de) Eine glucagon enthaltende pharmazeutische zubereitung
IT9019421A0 (it) Formulazioni acquose stabilizzate di piccoli peptidi.
PT814782E (pt) Composicao farmaceutica estabilizada com um agente basico
DK1172114T3 (da) Stabile koncentrerede insulinpræparater til pulmonær indgivelse
ATE293433T1 (de) Formulierungen mit antiviraler wirkung
ATE286057T1 (de) Pharmazeutische zubereitungen enthaltend clavulansäure
IS7043A (is) Lyfjagjöf efnafræðilega umbreytts insúlíns í lungu
CY1105465T1 (el) Μορφη δοσολογιας πepιλαμβανουσα υγρο σκευασμα
NO996323L (no) Medisinske blandinger for anvendelse på mukosa
DE60143363D1 (de) Pharmazeutische zusammensetzungen, die die immunogenität von schwach immunogenen antigenen fördern
DE69723278D1 (de) Pharmazeutische ampulle
IS6654A (is) Stöðugt gabapentín með pH innan stýrðra marka
ATE264340T1 (de) Stabilisierung von gefriergetrocknetem kuchen
DK0797997T3 (da) Anvendelse af peptidiske bradykinin-antagonister til fremstilling af lægemidler
ES2092559T3 (es) Formulacion farmaceutica que contiene penciclovir.
ATE113965T1 (de) Stabilisierte, starke grf-analoga.
IT1280863B1 (it) Procedimento per produrre una forma attiva di incenso e relativo uso dell'incenso stesso.
ITRM20010731A1 (it) Procedimento per la produzione di emulsioni acquose stabili di sostanze lipofile di interesse farmaceutico ed emulsioni cosi' ottenute.
TH43906B (th) อินเทอร์ลูคิน 2 ที่ถูกทำให้เสถียรแล้ว
MX9707121A (es) Formulaciones liquidas de gch.